Blood Sugar Molecules Called Glycans May Predict and Reverse Biological Aging
A 20,000-person study finds IgG glycan patterns track biological aging, predict mortality, and shift toward youth with interventions.
Summary
Researchers analyzing data from over 20,000 people across 42 studies found that tiny sugar molecules attached to immune antibodies — called IgG glycans — closely track biological aging and can predict risk of death independent of chronological age. More strikingly, these glycan patterns appear to shift in a more youthful direction in response to certain interventions. Caloric restriction, hormone replacement therapy, and therapeutic plasma exchange all showed effects, with plasma exchange producing the strongest change — roughly 0.4 years of glycan age reduction per month. Led by Professor Gordan Lauc of GlycanAge and the University of Zagreb, the research positions IgG glycans as both a measurable aging biomarker and a potential therapeutic target for extending healthspan.
Detailed Summary
Aging does not just show up on the surface — it leaves measurable chemical signatures in the bloodstream years before visible decline begins. A major new study focusing on glycans, sugar molecules attached to immune antibodies called IgG, suggests these signatures may be among the most informative aging biomarkers identified to date.
The research, described as the largest analysis of its kind, pooled data from more than 20,000 individuals across 42 independent studies spanning nearly two decades. Scientists found that specific glycan patterns on IgG antibodies shift predictably with age and chronic inflammation — the same low-grade immune overactivation tied to cardiovascular disease, cognitive decline, and frailty. Critically, glycan signatures independently predicted all-cause mortality, meaning they captured biological aging beyond what chronological age alone could explain.
The most headline-grabbing finding is that glycan patterns are not fixed. Three interventions — caloric restriction, hormone replacement therapy, and therapeutic plasma exchange — were all associated with shifts in glycan profiles toward younger biological states. Monthly therapeutic plasma exchange produced the largest effect, reducing glycan age by approximately 0.4 years per month under longitudinal monitoring. This is not a claim that people became chronologically younger, but that measurable immune-aging markers moved in a favorable direction.
The study was led by Professor Gordan Lauc of GlycanAge and the University of Zagreb, with collaborators from the Buck Institute for Research on Aging, King's College London, and more than 20 institutions globally. The scale and rigor of the meta-analysis lend the findings considerable weight within the longevity research community.
Caveats remain important. Therapeutic plasma exchange is not a consumer-ready intervention, and the mechanisms linking glycan changes to actual health outcomes need further investigation. Still, the research strengthens the case for IgG glycosylation as a modifiable, clinically trackable aging biomarker — a meaningful step toward personalized longevity medicine.
Key Findings
- IgG glycan patterns independently predict all-cause mortality beyond what chronological age alone indicates.
- Analysis covered 20,000+ individuals across 42 studies, making it the largest glycan-aging review to date.
- Therapeutic plasma exchange reduced glycan biological age by roughly 0.4 years per month in monitored participants.
- Caloric restriction and hormone replacement therapy also shifted glycan profiles toward younger biological states.
- Glycans may serve as a modifiable biomarker, meaning biological aging markers can potentially be moved in a healthier direction.
Methodology
This is a research summary reporting on a large-scale meta-analysis published by Professor Gordan Lauc and collaborators across more than 20 global institutions. The evidence basis is a pooled review of 42 independent studies involving over 20,000 participants spanning nearly two decades, which represents a high-quality epidemiological foundation. The source, Longevity.Technology, is a credible science journalism outlet covering aging research.
Study Limitations
The article summarizes a meta-analysis but does not provide the full paper's statistical details or effect sizes for all interventions. Glycan age reduction does not yet have an established direct causal link to improved clinical outcomes or extended lifespan. Readers should consult the primary paper — titled 'The Immunoglobulin G Glycome: A Modifiable Biomarker and Functional Effector of Aging, Disease, and Mortality' — for complete methodology and caveats.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.